COVID-19 and thrombotic risk in patients with active cancer: a matched cohort study.

Authors

Jérôme Doyen, Alexandre Lacour, Renaud Schiappa, Eva Seutin, Amanda Garrido, Tanguy Pace Loscos, Denis Doyen

Published in

JNCI cancer spectrum. Oct 12, 2026. Epub Oct 12, 2026.

Abstract

COVID-19 has been associated with an increased thrombotic risk, potentially exacerbated in patients with active cancer. We conducted a retrospective cohort study including 119 cancer patients with COVID-19 and 214 matched pre-pandemic controls. Patients with COVID-19 had poorer performance status and were more frequently treated with palliative intent. After a median follow-up of 32.7 months, overall thrombotic event rates did not differ between groups. However, after adjustment for clinically relevant covariates and accounting for death as a competing event, COVID-19 status and palliative treatment intent remained independently associated with a higher cumulative incidence of thrombotic events. In conclusion, COVID-19 may increase thrombotic risk in patients with cancer and occurs more frequently in patients with poorer clinical status. These findings are exploratory and require confirmation in larger prospective studies.

PMID:
42862724
Bibliographic data and abstract were imported from PubMed on 13 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.